55
45
Growth Score
-19 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
262619
IMVARIA brings artificial intelligence to imaging and lab data, re-imagining clinical assessments in serious diseases.
- Michael Muelly: Chief Technology Officer and Co-FounderPast Role: Google, Product Manager
Joshua Reicher: Chief Executive Officer and Co-Founder
About the Company
IMVARIA is advancing noninvasive AI biomarkers for better patient lives. We bring artificial intelligence to imaging and lab data, re-imagining clinical assessments in serious diseases.
IMVARIA serves Fibresolve -- the first AI diagnostic tool in interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF). Fibresolve is an FDA
Breakthrough Device and is authorized by the FDA to serve as an adjunctive, non-invasive diagnostic tool for patients with suspected ILD and IPF.
Beyond ILD and IPF, IMVARIA is developing AI biomarkers in multiple areas including oncology, pulmonology, immunology, and more.
